Cardiotoxicity and the Evolving Landscape of HER2-Targeted Breast Cancer Treatment
Cancer therapies associated with cardiotoxicity risk including anthracyclines and HER2-targeted agents remain important cornerstones of curative and life-prolonging breast cancer treatment.
